Dose-response relationships in aluminium toxicity in humans

References

• Affourtit F, Bakker MI, Pronk MEJ. Human health risk assessment of aluminium. Netherlands: Dutch National Institute for Public Health and the Environment, RIVM Report; 2020.
   Google Scholar
• Scientific Opinion of the Panel on Food Additives, Flavourings, processing aids and food contact materials on a request from european commission on safety of aluminium from dietary intake. The EFSA Journal. 2008;754:1–34.
   Google Scholar
• Mitchell J, Manning GB, Molyneux M, et al. Pulmonary fibrosis in workers exposed to finely powdered aluminium. Br J Ind Med. 1961;18:10–23.
   PubMedGoogle Scholar
• McLaughlin AI, Kazantzis G, King E, et al. Pulmonary fibrosis and encephalopathy associated with the inhalation of aluminium dust. Br J Ind Med. 1962;19:253–263.
   PubMedGoogle Scholar
• Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294(4):184–188.
   PubMed Web of Science ®Google Scholar
• Parkinson IS, Ward MK, Kerr DN. Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol. 1981;34(11):1285–1294.
   PubMed Web of Science ®Google Scholar
• Elliott HL, Dryburgh F, Fell GS, et al. Aluminium toxicity during regular haemodialysis. Br Med J. 1978;1(6120):1101–1103.
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; Oct42(4 Suppl 3):S1–S201.
   PubMed Web of Science ®Google Scholar
• Bishop NJ, Morley R, Day JP, et al. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med. 1997;336(22):1557–1561.
   PubMed Web of Science ®Google Scholar
• Perl T, Kunze-Szikszay N, Bräuer A, et al. Aluminium release by coated and uncoated fluid-warming devices. Anaesthesia. 2019;74(6):708–713.
   PubMed Web of Science ®Google Scholar
• Taylor MH, Choi D, Fitzpatrick SM, et al. Characterisation of aluminium release by the enFlow® fluid-warming system in crystalloids and blood products. Anaesthesia. 2019;74(11):1374–1380.
   PubMed Web of Science ®Google Scholar
• Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit. 2004;6(5):375–403.
   PubMedGoogle Scholar
• Steinhausen C, Kislinger G, Winklhofer C, et al. Investigation of the aluminium biokinetics in humans: a 26Al tracer study. Food Chem Toxicol. 2004;42(3):363–371.
   PubMed Web of Science ®Google Scholar
• Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol. 2001;88(4):159–167.
   PubMedGoogle Scholar
• Newton D, Talbot RJ. Long-term retention of injected aluminium-26. Hum Exp Toxicol. 2012;31(12):1195–1198.
   PubMed Web of Science ®Google Scholar
• Berlyne GM, Adler AJ. Serum aluminum cannot be measured accurately. Am J Kidney Dis. 1985;6(5):288–292.
   PubMed Web of Science ®Google Scholar
• European Commission Resolution of the council and the representatives of the member states, meeting within the council of 16 june 1986 concerning the protection of dialysis patients by minimizing the exposure to aluminium (86/C184/04). Official Journal of the European Communities. 1986;184(No C):16–18.
   Google Scholar
• Nadel AM, Wilson WP. Dialysis encephalopathy: a possible seizure disorder. Neurology. 1976;26(12):1130–1134.
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Couttenye MM, De Broe ME. Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant. 1996;11 Suppl 3:74–79.
   PubMed Web of Science ®Google Scholar
• de Wolff FA, van der Voet GB. Biological monitoring of aluminium in renal patients. Clin Chim Acta. 1986;160(2):183–188.
   PubMed Web of Science ®Google Scholar
• Taylor A, Walker AW. Measurement of aluminium in clinical samples. Ann Clin Biochem. 1992;29(4):377–389.
   PubMedGoogle Scholar
• Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5–14.
   Web of Science ®Google Scholar
• Wells GS, O'Connell D, Peterson J, et al. The Newcastle- Ottawa scale (NOS) for assessing the quality of nonrandomised studies in Meta- analyses. Ottawa: Ottawa Hospital Research Institute; 2008. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [accessed 5th July 2019].
   Google Scholar
• Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63.
   PubMedGoogle Scholar
• Maharaj D, Fell GS, Boyce BF, et al. Aluminium bone disease in patients receiving plasma exchange with contaminated albumin. Br Med J (Clin Res Ed). 1987;295(6600):693–696.
   PubMedGoogle Scholar
• Köppel C, Baudisch H, Ibe K. Inadvertent metal loading of critically ill patients with acute renal failure by human albumin solution infusion therapy. J Toxicol Clin Toxicol. 1988;26(5-6):337–356.
   PubMed Web of Science ®Google Scholar
• McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant. 1989;4(2):110–114.
   PubMed Web of Science ®Google Scholar
• Jenkins DA, Gouldesbrough D, Smith GD, et al. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant. 1989;4(1):51–56.
   PubMed Web of Science ®Google Scholar
• Candy JM, McArthur FK, Oakley AE, et al. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci. 1992;107(2):210–218.
   PubMed Web of Science ®Google Scholar
• Campistrus de Gencarelli N, Cournot-Witmer G, Zingraff J, et al. The role of parathyroid function and parathyroidectomy in the outcome of aluminium-related dialysis encephalopathy. Nephrol Dial Transplant. 1986;1(3):192–198.
   PubMedGoogle Scholar
• Smith GD, Winney RJ, McLean A, et al. Aluminium-related osteomalacia: response to reverse osmosis water treatment. Kidney Int. 1987;32(1):96–101.
   PubMed Web of Science ®Google Scholar
• Sedman AB, Klein GL, Merritt RJ, et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med. 1985;312(21):1337–1343.
   PubMed Web of Science ®Google Scholar
• Adhemar JP, Laederich J, Jaudon MC, et al. Removal of aluminium from patients with dialysis encephalopathy. Lancet. 1980;2(8207):1311.
   PubMed Web of Science ®Google Scholar
• Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int. 2001;59(2):746–753.
   PubMed Web of Science ®Google Scholar
• Sherrard DJ, Ott SM, Andress DL. Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure. Am J Med. 1985;79(1):127–130.
   PubMed Web of Science ®Google Scholar
• Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9–11.
   PubMed Web of Science ®Google Scholar
• Russo LS, Beale G, Sandroni S, et al. Aluminium intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psychiatry. 1992;55(8):697–700.
   PubMedGoogle Scholar
• Sedman AB, Miller NL, Warady BA, et al. Aluminum loading in children with chronic renal failure. Kidney Int. 1984;26(2):201–204.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Fell GS, Elder HY, et al. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet. 1982;2(8306):1009–1013.
   PubMedGoogle Scholar
• O'Brien AA, Moore DP, Keogh JA. Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders. Ir J Med Sci. 1990;159(3):74–76.
   PubMed Web of Science ®Google Scholar
• Phelps KR, Naylor K, Brien TP, et al. Encephalopathy after bladder irrigation with alum: case report and literature review. Am J Med Sci. 1999;318(3):181–185.
   PubMed Web of Science ®Google Scholar
• Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis. 1988;12(2):126–130.
   PubMed Web of Science ®Google Scholar
• Bakir AA, Hryhorczuk DO, Berman E, et al. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. ASAIO Trans. 1986;32(1):171–176.
   PubMedGoogle Scholar
• Pillion G, Loirat C, Blum C, et al. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure. Int J Pediatr Nephrol. 1981;2(1):29–32.
   PubMedGoogle Scholar
• O'Brien AA, McParland C, Keogh JA. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia. Nephrol Dial Transplant. 1987;2(2):117–119.
   PubMedGoogle Scholar
• Maher ER, Brown EA, Curtis JR, et al. Accumulation of aluminium in chronic renal failure due to administration of albumin replacement solutions. Br Med J (Clin Res Ed). 1986;292(6516):306.
   PubMedGoogle Scholar
• Fenwick S, Roberts EA, Mahesh BS, et al. In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring. Ann Clin Biochem. 2005;42(2):149–152.
   PubMedGoogle Scholar
• Terao N, Sizuki M, Ando Y, et al. Kinetics of aluminium removal by desferrioxamine via hemodialysis in a case of aluminium bone disease. Japan J Nephrol. 1985;27:1305–1312.
   Google Scholar
• Nakamura H, Rose PG, Blumer JL, et al. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. J Clin Pharmacol. 2000;40(3):296–300.
   PubMed Web of Science ®Google Scholar
• Arze RS, Parkinson IS, Cartlidge NE, et al. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Lancet. 1981;2(8255):1116.
   PubMed Web of Science ®Google Scholar
• Payton CD, Junor BJ, Fell GS. Successful treatment of aluminium encephalopathy by intraperitoneal desferrioxamine. Lancet. 1984;1(8386):1132–1133.
   PubMed Web of Science ®Google Scholar
• Pogglitsch H, Petek W, Wawschinek O, et al. Treatment of early stages of dialysis encephalopathy by aluminium depletion. Lancet. 1981;2(8259):1344–1345.
   PubMed Web of Science ®Google Scholar
• Bauer TW, Popowniak KL, Stulberg BN, et al. Osteomalacia associated with aluminum intoxication in a patient with chronic renal failure. Cleve Clin Q. 1985;52(2):271–278.
   PubMedGoogle Scholar
• Zachee P, Boogaerts MA, Lins RL, et al. Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet. 1990;335(8696):1038–1039.
   PubMedGoogle Scholar
• Kanwar VS, Jenkins JJ, 3rd, Mandrell BN, et al. Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Med Pediatr Oncol. 1996;27(1):64–67.
   PubMedGoogle Scholar
• Sprague SM, Corwin HL, Wilson RS, Mayor GH, et al. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986;146(10):2063–2064.
   PubMedGoogle Scholar
• Warady BA, Ford DM, Gaston CE, et al. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine. Pediatrics. 1986;78(4):651–655.
   PubMed Web of Science ®Google Scholar
• Geary DF, Fennell RS, Andriola M, et al. Encephalopathy in children with chronic renal failure. J Pediatr. 1980;97(1):41–44.
   PubMed Web of Science ®Google Scholar
• Zatta P, Zambenedetti P, Reusche E, et al. A fatal case of aluminium encephalopathy in a patient with severe chronic renal failure not on dialysis. Nephrol Dial Transplant. 2004;19(11):2929–2931.
   PubMed Web of Science ®Google Scholar
• Andrade LG, Garcia FD, Silva VS, et al. Dialysis encephalopathy secondary to aluminum toxicity, diagnosed by bone biopsy. Nephrol Dial Transplant. 2005;20(11):2581–2582.
   PubMed Web of Science ®Google Scholar
• Shirabe T, Irie K, Uchida M. Autopsy case of aluminum encephalopathy. Neuropathology. 2002;22(3):206–210.
   PubMed Web of Science ®Google Scholar
• Dahl E, Nordal KP, Halse J, et al. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study. Nephrol Dial Transplant. 1990;5(6):449–456.
   PubMed Web of Science ®Google Scholar
• Charhon SA, Chavassieux PM, Meunier PJ, et al. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis. Br Med J (Clin Res Ed). 1985;290(6482):1613–1614.
   PubMedGoogle Scholar
• Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis. 1999;34(4):688–693.
   PubMed Web of Science ®Google Scholar
• Andress DL, Maloney NA, Endres DB, et al. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986;1(5):391–398.
   PubMed Web of Science ®Google Scholar
• Tsunoda A, Nakagi M, Kano N, et al. Serum aluminum levels in dialysis patients after sclerotherapy of internal hemorrhoids with aluminum potassium sulfate and tannic acid. Surg Today. 2014;44(12):2314–2317.
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Clement JP, Elseviers MM, et al. Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol Dial Transplant. 1990;5(1):45–53.
   PubMedGoogle Scholar
• Hodsman AB, Steer BM. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol. 1992;2(8):1318–1327.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Toussaint ND, Pickering J, et al. Assessing the utility of testing aluminum levels in dialysis patients. Hemodial Int. 2015;19(2):256–262.
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Perruzza I, Costantini S, et al. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients. Nephrol Dial Transplant. 1997;12(12):2679–2682.
   PubMed Web of Science ®Google Scholar
• Gault PM, Allen KR, Newton KE. Plasma aluminium: a redundant test for patients on dialysis? Ann Clin Biochem. 2005;42(Pt 1):51–54.
   PubMedGoogle Scholar
• Graf H, Stummvoll HK, Meisinger V. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis. Proc Eur Dial Transplant Assoc. 1981;18:674–680.
   PubMedGoogle Scholar
• McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med. 1990;74(275):257–276.
   PubMedGoogle Scholar
• Gilli P, Malacarne F, Fagioli F. Is serum aluminium monitoring useful in evaluating aluminium intoxication? Lancet. 1983;1(8325):656.
   PubMed Web of Science ®Google Scholar
• Jaudon MC, Coz BL, Clavel JP. More on Al contamination of samples for Al analysis. Clin Chem. 1985;31(4):660–661.
   PubMedGoogle Scholar